One Biosciences gets €3.3 million France 2030 grant for breast-cancer diagnostic
The non-dilutive award with Institut Curie will accelerate One Biosciences’ first single-cell diagnostic for triple-negative breast cancer.
From tumour profiling to a targeted diagnostic
One Biosciences’ OneMap platform analyzes tumour samples at single-cell resolution, combining sample preparation, RNA sequencing and AI to show how tumour, stromal and immune cells differ. That detail can reveal biological signals that bulk sequencing may mask.
The €3.3 million i-Démo 5 award under France 2030 supports the company’s first single-cell diagnostic for triple-negative breast cancer, developed with Institut Curie. The project moves the platform toward a defined clinical application: identifying meaningful variation inside a tumour to inform oncology decisions.
Use of funds
Accelerate development of a single-cell diagnostic for triple-negative breast cancer